• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

减重手术与代谢相关脂肪性肝病:2022 年更新。

Bariatric Surgery and Metabolic Dysfunction-Associated Fatty Liver Disease: a 2022 Update.

机构信息

Clarunis, Department of Visceral Surgery, University Centre for Gastrointestinal and Liver Diseases, St. Clara Hospital and University Hospital Basel, Basel, Switzerland.

Chirurgie Zentrum St. Anna, Lucerne, Switzerland.

出版信息

Praxis (Bern 1994). 2023 Feb;112(2):97-102. doi: 10.1024/1661-8157/a003969.

DOI:10.1024/1661-8157/a003969
PMID:36722105
Abstract

Non-alcoholic fatty liver disease (NAFLD) has been recently termed metabolic dysfunction-associated fatty liver disease (MAFLD) to address the strong association with the metabolic syndrome. The prevalence of MAFLD is significantly increased in obese individuals and treatment of obesity is currently the cornerstone of management of MAFLD. Bariatric and metabolic surgery nowadays emerges as a key therapeutic strategy for the treatment of the MAFLD. This review aims to provide an update on the novel studies reporting the outcomes of bariatric surgery on the spectrum of MAFLD, from hepatic steatosis to cirrhosis.

摘要

非酒精性脂肪性肝病(NAFLD)最近被称为代谢功能障碍相关脂肪性肝病(MAFLD),以解决其与代谢综合征的强烈关联。肥胖人群中 MAFLD 的患病率显著增加,而肥胖的治疗目前是 MAFLD 管理的基石。如今,减重和代谢手术已成为治疗 MAFLD 的关键治疗策略。本综述旨在提供最新的研究报告,这些研究报告了减重手术对 MAFLD 谱,从肝脂肪变性到肝硬化的结果。

相似文献

1
Bariatric Surgery and Metabolic Dysfunction-Associated Fatty Liver Disease: a 2022 Update.减重手术与代谢相关脂肪性肝病:2022 年更新。
Praxis (Bern 1994). 2023 Feb;112(2):97-102. doi: 10.1024/1661-8157/a003969.
2
Bariatric surgery and non-alcoholic fatty liver disease.减重手术与非酒精性脂肪性肝病。
Med Clin (Barc). 2022 Jun 10;158(11):550-555. doi: 10.1016/j.medcli.2021.12.003. Epub 2022 Feb 2.
3
Mid-term Effects of Bariatric Surgery on Metabolic Dysfunction-Associated Fatty Liver Disease Remission and Predictive Factors: A Prospective Study with a Focus on Non-invasive Diagnosis.减重手术对代谢相关脂肪性肝病缓解的中期效果及预测因素:一项以非侵入性诊断为重点的前瞻性研究。
Obes Surg. 2024 Mar;34(3):841-849. doi: 10.1007/s11695-024-07071-1. Epub 2024 Jan 29.
4
Considerations for bariatric surgery in patients with cirrhosis.肝硬化患者行减重手术的相关考虑。
World J Gastroenterol. 2018 Jul 28;24(28):3112-3119. doi: 10.3748/wjg.v24.i28.3112.
5
Bariatric surgery for non-alcoholic fatty liver disease in individuals with obesity (Base-NAFLD): protocol of a prospective multicenter observational follow-up study.肥胖人群非酒精性脂肪性肝病的减重手术(基础-NAFLD):一项前瞻性多中心观察随访研究方案。
BMC Surg. 2021 Jun 24;21(1):298. doi: 10.1186/s12893-021-01296-y.
6
The Role Bariatric Surgery and Endobariatric Therapies in Nonalcoholic Steatohepatitis.减重手术和内镜减重治疗在非酒精性脂肪性肝炎中的作用
Clin Liver Dis. 2023 May;27(2):413-427. doi: 10.1016/j.cld.2023.01.009. Epub 2023 Feb 26.
7
Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes.非酒精性脂肪性肝病和 2 型糖尿病患者的发病机制、筛查方式和治疗选择。
Diabet Med. 2020 Nov;37(11):1793-1806. doi: 10.1111/dme.14356. Epub 2020 Jul 13.
8
Simultaneous living donor liver transplant with sleeve gastrectomy for metabolic syndrome and NASH-related ESLD-First report from India.同期活体供肝肝移植联合袖状胃切除术治疗代谢综合征和非酒精性脂肪性肝炎相关终末期肝病——来自印度的首例报告
Indian J Gastroenterol. 2017 May;36(3):243-247. doi: 10.1007/s12664-017-0753-5. Epub 2017 May 31.
9
Endoscopic Bariatric Interventions in Patients with Chronic Liver Disease.内镜减重术治疗慢性肝病患者
Clin Liver Dis. 2022 Feb;26(1):139-148. doi: 10.1016/j.cld.2021.08.005. Epub 2021 Sep 16.
10
The HAALT Non-invasive Scoring System for NAFLD in Obesity.HAALT 非肥胖性非酒精性脂肪肝病无创评分系统。
Obes Surg. 2019 Aug;29(8):2562-2570. doi: 10.1007/s11695-019-03880-x.

引用本文的文献

1
Pioglitazone with SGLT2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes and non-alcoholic fatty liver disease: could the combinations of an old friend with new players yield better outcomes?2型糖尿病合并非酒精性脂肪性肝病患者使用吡格列酮联合SGLT2抑制剂或GLP-1受体激动剂:老朋友与新药物联合使用能否产生更好的疗效?
Arch Med Sci Atheroscler Dis. 2025 Mar 14;10:e1-e15. doi: 10.5114/amsad/202298. eCollection 2025.
2
Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment.肥胖的临床分类及其对代谢功能障碍相关脂肪性肝病和治疗的影响
Diabetes Metab Syndr Obes. 2023 Oct 25;16:3303-3329. doi: 10.2147/DMSO.S431251. eCollection 2023.